3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
3
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
9
Recurrence
2
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
1
Leukemia, Plasma Cell
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Neoplasms
1
Amyloidosis
1
Interventions
fludarabine
6
Cyclophosphamide
5
fludarabine phosphate
4
Whole-Body Irradiation
4
itacitinib
3
angiotensin I (1-7)
3
pembrolizumab
2
Tacrolimus
2
Olanzapine
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
INCB039110
2
CTLA-4 Antigen
2
Busulfan
2
Brentuximab Vedotin
2
Bendamustine Hydrochloride
2
AP 1903 reagent
2
tazemetostat
1
tafasitamab
1
ruxolitinib
1
pomalidomide
1
ofatumumab
1
merphos
1
lopinavir-ritonavir drug combination
1
ivosidenib
1
ibrutinib
1
fedratinib
1
enasidenib
1
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Hematologic Neoplasms
×
daratumumab
×
Clear all
NCT05205252
2023-08-15
ARIA
Ipsen
Phase 1/2
Withdrawn